OA12046A - 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. - Google Patents

3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. Download PDF

Info

Publication number
OA12046A
OA12046A OA1200200051A OA1200200051A OA12046A OA 12046 A OA12046 A OA 12046A OA 1200200051 A OA1200200051 A OA 1200200051A OA 1200200051 A OA1200200051 A OA 1200200051A OA 12046 A OA12046 A OA 12046A
Authority
OA
OAPI
Prior art keywords
cyclopropyl
pyrazol
acetamide
phenyl
biphenyl
Prior art date
Application number
OA1200200051A
Other languages
English (en)
Inventor
Paolo Pevarello
Paolo Orsini
Gabriella Traquandi
Mario Varasi
Edward L Fritzen
Martha Warpehoski
Betsy PIERCE
Maria Grabriella Brasca
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of OA12046A publication Critical patent/OA12046A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200200051A 1999-08-12 2000-05-05 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. OA12046A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37283199A 1999-08-12 1999-08-12

Publications (1)

Publication Number Publication Date
OA12046A true OA12046A (en) 2006-05-02

Family

ID=23469802

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200051A OA12046A (en) 1999-08-12 2000-05-05 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents.

Country Status (35)

Country Link
US (2) US7034049B1 (et)
EP (1) EP1202733B1 (et)
JP (1) JP2003507329A (et)
KR (1) KR20020060160A (et)
CN (1) CN1373662A (et)
AP (1) AP2002002442A0 (et)
AR (1) AR026122A1 (et)
AT (1) ATE305782T1 (et)
AU (1) AU4971400A (et)
BG (1) BG106480A (et)
BR (1) BR0013143A (et)
CA (1) CA2383555C (et)
CZ (1) CZ2002422A3 (et)
DE (1) DE60023012T2 (et)
DK (1) DK1202733T3 (et)
EA (1) EA005373B1 (et)
EE (1) EE200200065A (et)
ES (1) ES2249270T3 (et)
GE (1) GEP20053476B (et)
HK (1) HK1046866A1 (et)
HR (1) HRP20020128A2 (et)
HU (1) HUP0203542A3 (et)
IL (1) IL147923A0 (et)
IS (1) IS6265A (et)
MA (1) MA25493A1 (et)
MX (1) MXPA02001498A (et)
NO (1) NO20020684L (et)
NZ (1) NZ517237A (et)
OA (1) OA12046A (et)
PE (1) PE20010130A1 (et)
PL (1) PL353455A1 (et)
SK (1) SK1812002A3 (et)
WO (1) WO2001012189A1 (et)
YU (1) YU9602A (et)
ZA (1) ZA200201511B (et)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
KR20020060160A (ko) * 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
DK1268472T3 (da) 2000-02-07 2004-12-06 Bristol Myers Squibb Co 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
EP1278749B1 (en) 2000-04-25 2005-01-26 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
IL154016A0 (en) * 2000-08-31 2003-07-31 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
CA2434066A1 (en) * 2001-01-26 2002-09-12 Pharmacia Italia S.P.A. Chromane derivatives, process for their preparation and their use as antitumor agents
CA2438813C (en) * 2001-03-02 2008-07-29 F. Hoffmann-La Roche Ag Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) * 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP1436286B1 (en) * 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
WO2003046207A2 (en) * 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6593477B1 (en) 2002-10-29 2003-07-15 Eastman Kodak Company Synthesis of 3-acylaminopyrazoles
JP4926403B2 (ja) * 2002-12-10 2012-05-09 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染の処置もしくは予防のための化合物および方法
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7414067B2 (en) * 2003-03-27 2008-08-19 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
PT1636236E (pt) 2003-05-22 2013-12-16 Nerviano Medical Sciences Srl Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase
JP4220548B2 (ja) 2003-06-05 2009-02-04 エラン ファーマシューティカルズ，インコーポレイテッド アシル化されたアミノ酸・アミジルピラゾール、および関連化合物
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
ES2330451T3 (es) * 2004-01-16 2009-12-10 Wyeth Inhibidores a base de sulfonamidas heterociclicas de la produccion de beta-amiloides que contienen un azol.
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
BRPI0507278A (pt) * 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
CN101137631A (zh) * 2004-12-03 2008-03-05 转化技术制药公司 杂芳族葡糖激酶激活剂
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
US7361672B2 (en) * 2004-12-23 2008-04-22 Hoffmann-La Roche Inc. Heteroarylacetamide inhibitors of factor Xa
FR2880540B1 (fr) * 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
WO2007007886A1 (en) * 2005-07-11 2007-01-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
WO2007009898A1 (en) 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
CA2620878A1 (en) * 2005-08-29 2007-04-05 Gerard M. Housey Theramutein modulators
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
WO2007081966A2 (en) * 2006-01-09 2007-07-19 University Of Southern California Small molecules for treating cancer and abnormal cell proliferation disorders
WO2007095383A2 (en) * 2006-02-15 2007-08-23 Myriad Genetics, Inc. Prodrugs
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US8211925B2 (en) * 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
US20090118336A1 (en) * 2006-05-03 2009-05-07 Laurent David Pyrazole derivatives and their use as pi3k inhibitors
EP2049106A2 (en) * 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008084872A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
WO2008084873A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
JP5491871B2 (ja) * 2007-02-28 2014-05-14 アドビナス セラピュティックス プライベート リミテッド グルコキナーゼ活性化因子としての２，２，２−三置換アセトアミド誘導体、その方法及び薬学的応用
KR100923540B1 (ko) * 2007-11-23 2009-10-27 한국과학기술연구원 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
MX2010014234A (es) * 2008-06-19 2011-03-25 Astrazeneca Ab Compuestos pirazol 436.
CN102099352B (zh) 2008-07-10 2014-02-26 一般社团法人创药分子Ip 以喹啉甲酰胺衍生物为有效成分的stat3抑制剂
WO2010009985A2 (en) 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
HUE029289T2 (en) * 2008-12-05 2017-02-28 Abbvie Inc Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US20110288142A1 (en) * 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
WO2010129681A1 (en) * 2009-05-05 2010-11-11 Van Andel Research Institute Methods for treating autophagy-related disorders
JP2013502429A (ja) * 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
EP2491030B1 (en) 2009-10-22 2015-07-15 Fibrotech Therapeutics PTY LTD Fused ring analogues of anti-fibrotic agents
AU2010315190A1 (en) * 2009-11-05 2012-05-10 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
MX2012014273A (es) 2010-06-07 2013-03-22 Novomedix Llc Compuestos furanilo y su uso.
JP2013530180A (ja) 2010-06-16 2013-07-25 パーデュー、ファーマ、リミテッド、パートナーシップ アリール置換インドールおよびその使用
RU2576316C2 (ru) * 2010-11-03 2016-02-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидная композиция, способ контроля вредителей, способ контроля эндопаразитов, эктопаразитов или обоих и способ усиления жизнестойкости растений
US9073895B2 (en) * 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
EP2614065B1 (en) 2010-12-17 2017-04-19 Nerviano Medical Sciences S.r.l. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
US20140249105A1 (en) * 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
US9056867B2 (en) * 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
JP6027128B2 (ja) 2011-10-26 2016-11-16 ダウ アグロサイエンシィズ エルエルシー 有害生物防除組成物およびそれに関連した方法
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
BR122014028247A2 (pt) 2012-04-27 2019-05-07 Dow Agrosciences Llc composições pesticidas, processo para controlar praga, uso de uma molécula, processo para aumentar a saúde, rendimento, vigor, qualidade ou tolerância de uma planta e processos para produção de compostos
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN103936637B (zh) * 2013-01-18 2016-04-06 北京大学 E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
BR112015023618A2 (pt) 2013-03-15 2017-07-18 Glaxosmithkline Ip Dev Ltd derivados de piridina como inibidores de quinase reorganizada durante a transfecção (ret)
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
MA38394B1 (fr) 2013-03-15 2018-04-30 Glaxosmithkline Ip Dev Ltd Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
EP2996689A1 (en) * 2013-04-17 2016-03-23 Albert-Ludwigs-Universität Freiburg Compounds for use as bromodomain inhibitors
CN103265535B (zh) * 2013-05-14 2015-06-17 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
KR20160055170A (ko) * 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004941A (es) * 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
JP2016539092A (ja) 2013-10-17 2016-12-15 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
CA2926095A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
US9029554B1 (en) 2013-10-17 2015-05-12 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2925953C (en) 2013-10-17 2021-11-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3057429A4 (en) 2013-10-17 2017-08-09 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
US9801383B2 (en) 2013-10-22 2017-10-31 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
US9282740B2 (en) 2013-10-22 2016-03-15 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
MX2016005305A (es) 2013-10-22 2017-03-01 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
TW201517797A (zh) 2013-10-22 2015-05-16 Dow Agrosciences Llc 協同性殺蟲組成物及相關方法（十一）
US9295260B2 (en) 2013-10-22 2016-03-29 Dow Agrosciences Llc Pesticidal compositions and related methods
KR20160074628A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
AR098101A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y métodos relacionados
AR098100A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y los métodos relacionados
NZ719776A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
EP3060044A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
JP2016535026A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
NZ719952A (en) 2013-10-22 2017-05-26 Dow Agrosciences Llc Pesticidal compositions and related methods
JP2016534073A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
US9788545B2 (en) 2013-10-22 2017-10-17 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AR098099A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas sinérgicas y los métodos relacionados
RU2656894C2 (ru) 2013-10-22 2018-06-07 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и соответствующие способы
AU2014340424B2 (en) 2013-10-22 2017-06-29 Dow Agrosciences Llc Pesticidal compositions and related methods
WO2015143653A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
JP2017523168A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
BR112017000293A2 (pt) 2014-07-31 2017-10-31 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
US9249122B1 (en) 2014-07-31 2016-02-02 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
JP2017525703A (ja) 2014-08-19 2017-09-07 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
EA032030B1 (ru) 2014-09-10 2019-03-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы
PE20170705A1 (es) 2014-09-10 2017-05-21 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
AR098113A1 (es) 2014-09-12 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
GB201416513D0 (en) * 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
CN107530329B (zh) 2015-03-09 2021-10-08 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物
BR112017023821A2 (pt) 2015-05-06 2018-07-31 Leidos Biomedical Res Inc moduladores de k-ras
CA2987552A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
CN118384166A (zh) * 2016-08-12 2024-07-26 阿西纳斯公司 用于调节激酶级联的联芳组合物和方法
CN110325036B (zh) 2016-12-29 2021-10-26 美国陶氏益农公司 用于制备杀虫化合物的方法
KR20190098204A (ko) * 2016-12-29 2019-08-21 엔요 파마 항바이러스제로서의 티오펜 유도체
JP2020503336A (ja) 2016-12-29 2020-01-30 ダウ アグロサイエンシィズ エルエルシー 殺有害生物化合物の調製方法
CA3052036A1 (en) 2017-02-03 2018-08-09 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
AU2018238138A1 (en) 2017-03-21 2019-10-17 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
BR112019021899A2 (pt) 2017-04-20 2020-08-18 The Regents Of The University Of California moduladores de k-ras
EP3720436A4 (en) 2017-12-06 2021-06-02 Lin Bioscience, Pty Ltd. TUBULIN INHIBITORS
WO2019148244A1 (en) * 2018-02-01 2019-08-08 The University Of Sydney Anti-cancer compounds
AU2019247885B2 (en) * 2018-04-04 2023-09-07 Aurigene Oncology Limited Substituted pyrazole derivatives as selective CDK12/13 inhibitors
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
US20230149414A1 (en) * 2020-01-29 2023-05-18 Foghorn Therapeutics Inc. Compounds and uses thereof
CN111793034B (zh) * 2020-07-24 2021-11-19 华中科技大学 苯并咪唑盐衍生物与制备抗肿瘤药物的应用
WO2022079290A2 (en) * 2020-10-16 2022-04-21 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Cullin ring ubiquitin ligase compounds and uses thereof
WO2022135442A1 (zh) * 2020-12-22 2022-06-30 上海拓界生物医药科技有限公司 Cdk2抑制剂及其制备方法
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
KR20240133695A (ko) * 2021-12-10 2024-09-04 프로테나 바이오사이언시즈 리미티드 Dyrk1a 억제제로서의 헤테로시클릭 화합물
WO2023203174A1 (en) * 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
CN116496151B (zh) * 2023-04-26 2024-08-23 长沙医学院 一种利用Catellani策略制备芴酮衍生物的方法
CN118221668A (zh) * 2024-03-19 2024-06-21 华南农业大学 一种含2-氨基-1,3,4-噻二唑的吲哚美辛衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
WO1996014843A2 (en) 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
CA2273102A1 (en) 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Urea derivatives
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
MXPA00006233A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
ID26328A (id) * 1997-12-22 2000-12-14 Bayer Ag Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril
KR20020060160A (ko) * 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
EP1202733A4 (en) 2003-05-14
EE200200065A (et) 2003-04-15
AR026122A1 (es) 2003-01-29
MA25493A1 (fr) 2002-07-01
PE20010130A1 (es) 2001-02-01
EA200200248A1 (ru) 2002-08-29
ES2249270T3 (es) 2006-04-01
NO20020684D0 (no) 2002-02-11
PL353455A1 (en) 2003-11-17
KR20020060160A (ko) 2002-07-16
BG106480A (en) 2002-09-30
CA2383555C (en) 2009-02-17
DE60023012T2 (de) 2006-07-20
CA2383555A1 (en) 2001-02-22
ZA200201511B (en) 2003-05-28
ATE305782T1 (de) 2005-10-15
EP1202733B1 (en) 2005-10-05
DK1202733T3 (da) 2005-10-31
US7034049B1 (en) 2006-04-25
CZ2002422A3 (cs) 2002-11-13
NO20020684L (no) 2002-04-03
EA005373B1 (ru) 2005-02-24
AU4971400A (en) 2001-03-13
SK1812002A3 (en) 2003-02-04
WO2001012189A8 (en) 2001-08-02
IL147923A0 (en) 2002-08-14
HK1046866A1 (zh) 2003-01-30
IS6265A (is) 2002-02-11
AP2002002442A0 (en) 2002-03-31
MXPA02001498A (es) 2003-07-21
EP1202733A1 (en) 2002-05-08
HUP0203542A2 (en) 2003-05-28
JP2003507329A (ja) 2003-02-25
WO2001012189A1 (en) 2001-02-22
HRP20020128A2 (en) 2003-04-30
YU9602A (sh) 2004-11-25
NZ517237A (en) 2004-02-27
BR0013143A (pt) 2002-06-11
DE60023012D1 (de) 2006-02-16
US6218418B1 (en) 2001-04-17
GEP20053476B (en) 2005-03-25
CN1373662A (zh) 2002-10-09
HUP0203542A3 (en) 2003-07-28

Similar Documents

Publication Publication Date Title
EP1202733B1 (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
AU2007284562B2 (en) Using PI3K and MEK modulators in treatments of cancer
EP1124810B9 (en) 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP2313399B1 (en) Thiophene or thiazole derivatives and their use as pi3k inhibitors
CN101111483B (zh) Igf-1r抑制剂
CN102458402A (zh) 用作激酶调节剂的烟酰胺化合物
CA2430151A1 (en) Phenylacetamido- pyrazole derivatives and their use as antitumor agents
WO2001012188A1 (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
ZA200606530B (en) (3-Oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
CA3029278A1 (en) Pyrazole compounds and compositions for the treatment of cancer
US20040116497A1 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
JPWO2007063868A1 (ja) アリールメチレンウレア誘導体及びその用途
WO2022237780A1 (zh) 酰胺衍生物及其应用
HK1157327B (en) Thiophene or thiazole derivatives and their use as pi3k inhibitors
HK1157327A (en) Thiophene or thiazole derivatives and their use as pi3k inhibitors